Search Results - "Baste N"

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.

Authors: Capdevila J Hernando J Molina-Cerillo J et al.

Source: Nature communications [Nat Commun] 2026 Apr 04; Vol. 17 (1). Date of Electronic Publication: 2026 Apr 04.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

An observational retro-prospective study on patients with head and neck cancer who contracted COVID-19 (HERODOTUS: head and neck cancERs international cOviD-19 collabOraTion).

Authors: Economopoulou P Pouliakis A Kyprianou M et al.

Source: Oral oncology [Oral Oncol] 2026 Apr; Vol. 175, pp. 107900. Date of Electronic Publication: 2026 Feb 20.

Publication Type: Journal Article; Observational Study; Multicenter Study

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9709118 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0593 (Electronic) Linking ISSN: 13688375 NLM ISO Abbreviation: Oral Oncol Subsets: MEDLINE

Targeting Oxidative Stress and Inflammation in Pembrolizumab-Induced Renal Injury: A Comparative Evaluation of the Protective Effects of Flunarizine and Carvacrol in Rats.

Authors: Hendem, Engin Yavuzer, Bulent Sezgin, Esra Tuba et al.

Source: Biomolecules (2218-273X). Jun2026, Vol. 16 Issue 6, p786. 19p.

Basic and Clinical Evidence for Perioperative Immunotherapy in Resectable HNSCC.

Authors: Sakaue, Shota Kono, Michihisa Kumai, Takumi et al.

Source: Cancers. Jun2026, Vol. 18 Issue 11, p1845. 17p.

Immunotherapy in Head and Neck Cancer—Where Are We Now and Where Are We Headed?

Authors: Becht, Rafał Kiełbowski, Kajetan Żukowska, Paulina et al.

Source: International Journal of Molecular Sciences. Jan2026, Vol. 27 Issue 2, p987. 22p.

Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas.

Authors: Knebel, Moritz Klamminger, Gilbert Georg Kühn, Jan Philipp et al.

Source: Cancers. Apr2026, Vol. 18 Issue 8, p1286. 18p.

Co-Stimulatory and Immune Checkpoint Molecule Expression on Peripheral Immune Cells Differs Age Dependently Between Healthy Donors and Patients with Head and Neck Squamous Cell Carcinoma.

Authors: Puntigam, Lisa K. Grages, Ayla Vahl, Julius M. et al.

Source: Cancers. Oct2025, Vol. 17 Issue 19, p3215. 13p.

Mitomycin-C for HPV-Positive and HPV-Negative Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial.

Authors: Oppelt, Peter Ley, Jessica Auberle, Christine et al.

Source: Cancers. Nov2025, Vol. 17 Issue 21, p3568. 15p.

Optimising Patient Outcomes in Tongue Cancer: A Multidisciplinary Approach.

Authors: de Boer, Jasper Barnett, Rebecca Cardin, Anthony et al.

Source: Cancers. Apr2024, Vol. 16 Issue 7, p1277. 13p.

Blood-Based Inflammatory Markers Are Associated with Treatment Outcomes in Head and Neck Squamous Cell Carcinoma Receiving Anti-PD-1 Therapy: CRP as a Superior Predictive Marker.

Authors: Stöth, Manuel Müller-Diesing, Flurin Mack, Patricia et al.

Source: International Journal of Molecular Sciences. Sep2025, Vol. 26 Issue 18, p9154. 12p.

Elucidating the role of N-myristoylation in the excessive membrane localization of PD-L1 in hypoxic cancers and developing a novel NMT1 inhibitor for combination with immune checkpoint blockade therapy.

Authors: Zhao, Haoming Zhang, Zhen Zhang, Chaojun et al.

Source: Journal of Experimental & Clinical Cancer Research (17569966). 7/2/2025, Vol. 44 Issue 1, p1-22. 22p.

Targeting DAMPs by Aspirin Inhibits Head and Neck Cancer Stem Cells and Stimulates Radio-Sensitization to Proton Therapy.

Authors: Vasiljevic, Tea Zapletal, Emilija Tarle, Marko et al.

Source: Cancers. Jul2025, Vol. 17 Issue 13, p2157. 23p.

Optimizing Preclinical Models for Oral Cancer: The Influence of 4NQO Administration Routes on Tumor Development.

Authors: Van den Bosch, Jolien Caz, Nuran Martens, Sandrina et al.

Source: Cancers. Jul2025, Vol. 17 Issue 13, p2108. 20p.

A novel model for predicting immunotherapy response and prognosis in NSCLC patients.

Authors: Zang, Ting Luo, Xiaorong Mo, Yangyu et al.

Source: Cancer Cell International. 5/15/2025, Vol. 25 Issue 1, p1-13. 13p.

Immunohistochemical expression of estrogen receptor-β in adenoid cystic carcinoma of salivary gland – A descriptive study.

Authors: Mujtaba, Hasan Ahmad, Shahzad Khan, Zafar Ali et al.

Source: Journal of Cancer Research & Therapeutics. Oct-Dec2024, Vol. 20 Issue 6, p1872-1877. 6p.

Immune Cell Deconvolution Reveals Possible Association of γδ T Cells with Poor Survival in Head and Neck Squamous Cell Carcinoma.

Authors: Parikh, Anuraag S. Li, Yize Mazul, Angela et al.

Source: Cancers. Oct2023, Vol. 15 Issue 19, p4855. 9p.

ACLP Activates Cancer-Associated Fibroblasts and Inhibits CD8+ T-Cell Infiltration in Oral Squamous Cell Carcinoma.

Authors: Sekiguchi, Shohei Yorozu, Akira Okazaki, Fumika et al.

Source: Cancers. Sep2023, Vol. 15 Issue 17, p4303. 17p.

Tobacco smoke exposure is a driver of altered oxidative stress response and immunity in head and neck cancer.

Authors: Li, Yang Yadollahi, Pedram Essien, Fonma N. et al.

Source: Journal of Translational Medicine. 4/5/2025, Vol. 23 Issue 1, p1-21. 21p.

HRAS Mutations in Head and Neck Carcinomas in Japanese Patients: Clinical Significance, Prognosis, and Therapeutic Potential.

Authors: Ohshima, Hidemi Kobayashi, Eiji Inaba, Manabu et al.

Source: International Journal of Molecular Sciences. Apr2025, Vol. 26 Issue 7, p3093. 14p.

EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancer.

Authors: Zhou, Jiefu He, Min Zhao, Qiong et al.

Source: Molecular Cancer. 3/22/2025, Vol. 24 Issue 1, p1-26. 26p.